Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study.

Young Youn ChoSu Jong YuHye Won LeeDo Young KimWonseok KangYong-Han PaikPil Soo SungSi Hyun BaeSu Cheol ParkYoung Seok DohKang Mo KimEun Sun JangIn Hee KimWon KimYun Joon Kim

Published in: Journal of hepatocellular carcinoma (2021)

This large, multicenter, retrospective study showed an objective response rate of 9.1% and a proportion of long-term survivors of 16.4% in Korean patients. The prognostic factors derived in our study can be used in clinical practice during sorafenib treatment.

Keyphrases

prognostic factors
end stage renal disease
young adults
chronic kidney disease
ejection fraction
squamous cell carcinoma
peritoneal dialysis
replacement therapy
rectal cancer